AI in Drug Discovery Funding: A Quarter-by-Quarter Analysis

All funding deals in the AI in drug discovery market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the AI In Drug Discovery Market.

Is AI drug discovery funding actually booming right now?

AI drug discovery funding looks much hotter in headline dollars than it does across the wider market today.

Across the five quarters we studied, total funding climbed from $185.3M in Q2 2025 to $400.6M, $665.9M, $1.203B and finally $2.314B. Read on its own, that looks like a market going vertical.

The rest of the numbers tell a less spectacular story. Deal count started at 14, peaked at 17 in Q4 2025 and finished back at 14. The median round rose from $7.35M to $23.2M by Q4, then dropped to $13M and $9.75M. Once we remove rounds above $50M, funding moves from $185.3M to $100.6M, $335.9M, $186.2M and $213.9M.

The big change has been at the very top of the market. Earendil Labs lifted Q1 2026 dramatically, then Isomorphic Labs pushed Q2 to a completely different scale. Ordinary funding activity has been much choppier.

There is also one useful timing caveat in Q2 2025. Sortera Bio announced its £7.5M pre-seed financing in June 2025, but the company's announcement says the round had actually closed in May 2024. Excluding it would reduce Q2 2025 to roughly $175M and 13 deals, without changing the overall picture.

Quarter	Deals	Total funding	Funding ex >$50M	Median round
Q2 2025	14	$185.3M	$185.3M	$7.35M
Q3 2025	11	$400.6M	$100.6M	$13.9M
Q4 2025	17	$665.9M	$335.9M	$23.2M
Q1 2026	16	$1.203B	$186.2M	$13.0M
Q2 2026	14	$2.314B	$213.9M	$9.75M

Which quarter was the real high point for AI drug discovery funding?

Q4 2025 was the strongest broad-based quarter for AI drug discovery funding in our five-quarter study.

It had the most deals at 17, the highest median financing at $23.2M and $335.9M of capital after removing rounds above $50M. That last figure was almost three times Q3's underlying funding and remained comfortably above both 2026 quarters.

The middle of the market was unusually strong too. Eight Q4 financings landed between $20M and $50M. AI Proteins raised $41.5M, Aureka Biotechnologies raised $23.2M, TandemAI raised $22M and Arpeggio Biosciences recorded roughly $20M. There was real depth across several companies instead of most of the money sitting in one blockbuster deal.

Larger financings still mattered. Chai Discovery raised $130M and Syneron Bio disclosed nearly $100M across its Series A and A+ closes. Yet Q4's biggest deal accounted for only 19.5% of the quarter, far below what happened next.

That is why Q4 stands out as the broad-market peak. The 2026 quarters brought more dollars, while fewer of those dollars reached the middle of the market.

Why did AI drug discovery funding jump in Q3 2025 even as deals fell?

Q3 2025 AI drug discovery funding jumped because three large follow-on rounds absorbed most of the capital even as fewer companies raised.

Deal count dropped from 14 to 11, but total funding more than doubled to $400.6M. Enveda raised $150M, CHARM Therapeutics raised $80M and Chai Discovery raised $70M. Together, those three financings represented 74.9% of the quarter.

There was still a genuine change underneath. The median round nearly doubled to $13.9M, while later-stage deals rose from 7.1% to 27.3% of activity. First financings also fell from 28.6% to 18.2%. Investors were putting more money behind companies that had already raised and progressed further.

The breadth was weak, though. Remove financings above $50M and Q3 funding falls to $100.6M, down 45.7% from Q2. Q3 looks much more like a shift toward bigger follow-on checks than the beginning of a market-wide surge.

Did AI drug discovery funding keep getting stronger in Q1 2026?

Q1 2026 AI drug discovery funding looked stronger on the surface, while the underlying market softened from Q4.

Headline capital jumped 81% to $1.203B. At the same time, deal count slipped from 17 to 16, the median round fell 44% and funding below the $50M threshold dropped to $186.2M.

Earendil Labs explains most of the difference. The company announced $787M in financing, equivalent to 65.4% of all Q1 capital in our calculations. Its own announcement described the amount as "$787 million in financing rounds," plural, without splitting those rounds by date or amount. We therefore treat the quarter's headline total with extra care.

Earendil was already operating at a very different level from a young discovery startup. The company said its AI platform had generated more than 40 biologics programs, with one antibody ready for Phase II development and further IND submissions planned. Syneron Bio added another $150M Series B, primarily to advance its macrocyclic-peptide platform and pipeline toward clinical development.

Q1 still contained healthy early-stage activity. Seed deals became more common and first financings started recovering. The funding distribution simply became much more skewed toward the few platforms already capable of absorbing very large amounts of capital.

Was Q2 2026's AI drug discovery funding record basically just Isomorphic Labs?

Q2 2026's AI drug discovery funding record was overwhelmingly an Isomorphic Labs event.

Isomorphic Labs raised $2.1B in Series B funding, representing 90.8% of all capital we recorded for the quarter. The company said the money would scale its AI drug-design engine globally and advance therapeutic programs toward the clinic.

Without that financing, Q2 falls from $2.314B to roughly $214M. That is still a modest improvement from Q1's funding below the $50M threshold, but it sits well below the broad Q4 2025 level.

The rest of the quarter looked much more ordinary. Aureka Biotechnologies raised $35M, Xellar Biosystems raised roughly $29M and Biossil raised $43M. Deal count declined from 16 to 14, while the median round fell to $9.75M.

So Q2 really had two markets running at once: normal venture activity across a group of smaller companies and one financing so large that it completely changed the chart.

Is AI drug discovery funding now concentrating around a few winners?

AI drug discovery capital is clearly concentrating around a smaller group of heavily funded platforms right now.

The biggest deal represented 19.5% of Q4 2025 funding, then 65.4% in Q1 2026 and 90.8% in Q2. Top-three concentration moved from 49.6% to 84.5% and then 94.6%.

The companies changed. Chai Discovery led Q4, Earendil dominated Q1 and Isomorphic Labs dominated Q2. We are seeing repeated concentration at the top rather than one company repeatedly raising every quarter.

There are signs that the pattern is continuing beyond our measurement window. Chai Discovery subsequently announced a $400M Series C, Aureka Biotechnologies closed a $100M Series B and Superluminal Medicines raised a $60M Series B. We keep those later rounds outside the quarterly calculations, but they reinforce the current appetite for companies that have moved from interesting AI technology toward scaled drug-development platforms.

The 90.8% Isomorphic share is obviously the extreme case. The broader shift is that investors now appear comfortable putting unusually large amounts of money behind a relatively small number of platforms once they reach the right level of scientific and commercial validation.

Quarter	Largest deal share	Top 3 share	Top 5 share	Capital from >$50M
Q2 2025	27.0%	62.1%	80.4%	0%
Q3 2025	37.4%	74.9%	88.9%	74.9%
Q4 2025	19.5%	49.6%	64.2%	49.6%
Q1 2026	65.4%	84.5%	89.3%	84.5%
Q2 2026	90.8%	94.6%	97.4%	90.8%

Are investors writing bigger AI drug discovery checks, or is the market splitting in two?

AI drug discovery checks are getting much bigger at the top, while ordinary rounds have actually shrunk since Q4 2025.

The clearest evidence comes from the deal-size distribution. Q4 had eight financings between $20M and $50M, almost half of all deals that quarter. By Q2 2026, four deals were below $5M, five were between $5M and $20M, four were between $20M and $50M, and Isomorphic sat alone above $100M.

The market is starting to look barbell-shaped. New companies can still raise a few million dollars. Proven platforms can raise hundreds of millions or even billions. The awkward part is the space in between, where financing breadth has stopped expanding.

This also makes the average round almost useless on its own. The Q2 2026 average reached roughly $165M, yet the median was below $10M. Most companies obviously were not raising anything close to $165M.

These days, the largest few deals tell us how much investors trust the winners. The median and the $20M–$50M bucket tell us much more about the health of everybody else.

Quarter	<$5M deals	$5M–<$20M	$20M–<$50M	$50M+
Q2 2025	7	3	3	1
Q3 2025	2	4	2	3
Q4 2025	2	3	8	4
Q1 2026	2	7	4	3
Q2 2026	4	5	4	1

Is De Novo Design really becoming the hottest part of AI drug discovery?

De Novo Design has the clearest sustained momentum in AI drug discovery funding today.

The category accounted for 35.7% of deals in Q2 2025, 36.4% in Q3, 41.2% in Q4 and 56.3% in Q1 2026. Its capital share also climbed sharply as investors backed companies building models that directly design new proteins, antibodies and small molecules.

Several companies make the trend easy to see. Chai Discovery moved from a $70M Series A in Q3 2025 to a $130M Series B in Q4. AI Proteins raised $41.5M to advance de novo miniprotein therapeutics. Boltz launched with $28M in Q1 2026 around biomolecular models and drug-design software. Isomorphic then produced the enormous Q2 financing.

The latest quarter needs one qualification. De Novo Design's deal share actually fell from 56.3% in Q1 to 35.7% in Q2, even as its capital share reached 94.8%. That capital figure mostly reflects Isomorphic rather than five different companies suddenly raising billion-dollar rounds.

Fresh activity after June strengthens the longer-term category case. Chai later raised $400M, Aureka raised $100M to expand its biological foundation models and closed-loop discovery system, and Superluminal raised $60M to move an AI-designed GPCR program toward the clinic. Those later deals suggest De Novo Design remains one of the areas where investors are most willing to fund the jump from models to actual drug programs.

Is AI Lead Generation losing investor attention?

AI Lead Generation lost real momentum in Q2 2026, although the category has been too volatile to call it a structural decline yet.

Its earlier funding path was unusually uneven. In Q3 2025, Lead Generation represented only one deal but 37.4% of all capital because Enveda raised $150M. By Q4, three companies raised money, and the category expanded again to four deals in Q1 2026.

That Q1 breadth looked more convincing because it included several companies rather than one oversized financing. Syneron Bio's $150M Series B also showed that investors were prepared to fund AI-enabled discovery platforms once they had a deeper experimental engine and a pipeline moving toward the clinic.

Then Q2 went quiet. Lead Generation fell to two deals, a $5M median round and only 0.4% of quarterly capital.

For now, that looks like a sharp latest-quarter reversal rather than proof that investors have moved on. The category has changed direction too often over five quarters to support a stronger claim.

Are investors cooling on Preclinical Prediction AI?

Preclinical Prediction AI is still producing deals, but investors are giving the category less capital relative to the rest of AI drug discovery.

Its funding intensity falls every quarter in our calculations, from 2.30 in Q2 2025 to 0.47, 0.32, 0.19 and finally 0.07. In plain English, the category keeps appearing in the deal count while taking a progressively smaller share of total dollars.

There are still meaningful financings. Vivodyne raised $40M around its lab-grown human tissue, robotics and predictive-AI platform. Bexorg raised $23M in fresh Series A capital to scale an AI-plus-whole-human-brain approach to CNS development. Turbine closed a $25M Series B around virtual-cell modeling, while Xellar Biosystems raised roughly $29M in Q2 2026.

Those are substantial venture rounds. They just look smaller next to the money flowing into platforms that design molecules directly and own increasingly mature therapeutic pipelines.

This is one of the clearer multi-quarter changes in the category data: activity remains alive, while relative capital intensity has steadily faded.

Are AI drug discovery investors moving toward older, later-stage companies?

AI drug discovery investors are still funding young companies heavily by count, while the biggest checks increasingly go to more mature platforms.

Seed and Series A together remain the majority of deals throughout the period. Early-stage companies represent between 63.6% and 78.6% of all financings in every quarter we studied. Q2 2026 actually had seven Seed deals, equal to half of the quarter's transactions.

Company age tells a similar story. Median age moves from four years in Q2 2025 to two, four, 3.5 and three years. We found no steady march toward older companies. First-financing companies are even younger, generally around one to two years old.

The maturity shift is much clearer in dollars. Earendil's financing came with more than 40 programs already generated by its platform and clinical development underway. Isomorphic's proceeds were earmarked partly for advancing therapeutic programs toward the clinic. Syneron's $150M financing was tied to pushing its macrocyclic-peptide pipeline into clinical development.

The market is funding two quite different stages at once. Young AI drug discovery startups keep entering at Seed and Series A, while the largest pools of capital increasingly sit with companies that can show a credible path from AI models to actual medicines.

Are brand-new AI drug discovery startups still getting funded?

Brand-new AI drug discovery startups are getting funded again, but they are raising small rounds.

First-financing share fell from 28.6% in Q2 2025 to 18.2% in Q3 and just 11.8% in Q4. It then recovered to 18.8% in Q1 2026 and 28.6% in Q2.

That recovery is visible in companies such as 10x Science, which raised $4.8M to build AI-native protein-characterization tools, ALP Bio, which raised $2.2M around immune organoids and generative AI, and Stoked Bio, which raised $2.5M around AI-guided drug discovery.

The money attached to those new entrants remains small. Four first financings in Q2 2026 raised only $19M combined, with a $3.65M median. Follow-on companies raised $2.295B, with a $23M median.

The startup pipeline therefore looks healthier by number of companies than by dollars. Investors are still willing to fund new teams, but the really large checks currently require much more proof.

Is North America losing ground in AI drug discovery funding?

North America still looks like the deepest AI drug discovery funding market by deal count today.

North American companies represented 43% to 59% of all deals in four of the five quarters. That pattern is much steadier than the capital numbers, which swing wildly depending on where the quarter's biggest company happens to be based.

Asia-Pacific captured 82.1% of Q1 2026 capital largely because Earendil and Syneron were recorded there. Europe then jumped to 91.5% in Q2 after London-based Isomorphic Labs raised $2.1B.

The company count barely supports such a dramatic geographic rotation. In Q2, North America still produced 57.1% of the deals even though it received only 7.7% of the capital.

For anyone trying to understand where the ecosystem is deepest, deal count currently gives a cleaner picture than quarterly dollars. Giant rounds make capital geography look far more unstable than the underlying company base really is.

Are the same VCs and pharma investors taking over AI drug discovery funding?

AI drug discovery capital is concentrating by company, but the investor base itself remains fairly broad. Pharma strategics are the group becoming more visible.

We found no disclosed lead investor appearing twice within the same quarter. Across the full five-quarter period, only a handful of names recur as disclosed leads or co-leads, including DNX Ventures, AIX Ventures, redalpine, Amplify Partners and DCVC. Each appears only twice. Q4 2025 alone had roughly 22 unique disclosed leads.

Strategic investors show a more directional change. Strategic-backed deals rose from 7.1% of activity in Q2 2025 to 27.3% in Q3 and 35.3% in Q4. The share later moderated, but the checks became much larger. The median strategic-backed round reached $73.75M in Q4 and $115M in Q1 2026.

The companies involved help explain why. Sortera Bio brought in AstraZeneca and BioNTech. Syneron had AstraZeneca among its existing investors. Earendil's investor group included Sanofi and a biotech fund created by Hillhouse and Pfizer. More recently, Superluminal's Series B again included existing investors NVIDIA and Eli Lilly.

Pharma and corporate investors appear most interested once an AI platform starts connecting directly to experimental validation, development programs and clinical assets. That pattern looks more durable than any concentration among traditional venture leads.

Quarter	Strategic-backed deals	Share of deals	Median strategic-backed round
Q2 2025	1	7.1%	$10.2M
Q3 2025	3	27.3%	$13.9M
Q4 2025	6	35.3%	$73.75M
Q1 2026	4	25.0%	$115M
Q2 2026	3	21.4%	$43M

What is the AI drug discovery funding trend actually telling us?

AI drug discovery funding has become much bigger at the top without becoming equally stronger across the full market. The record totals in 2026 say more about how much investors will pay for a few validated platforms than about the typical company raising money today.

Q4 2025 remains the best example of broad funding strength. It combined more deals, larger normal rounds and the deepest $20M–$50M financing cohort. The market has yet to reproduce that breadth.

Capital concentration is now hard to ignore. Three successive quarters were led by Chai Discovery, Earendil Labs and Isomorphic Labs, with the dominant company taking a larger share each time. Recent financings after our measurement window suggest investors still have a strong appetite for large platform-scale rounds.

The early-stage ecosystem remains active. Seed and Series A deals continue to dominate by number, and first financings recovered in 2026. The tension is further up the funding ladder, where the middle of the market looks less consistent than either small startup rounds or giant scale-up rounds.

De Novo Design currently has the clearest category momentum. The trend spans several companies and has continued beyond the end of our quarterly window, which gives us more confidence in it than categories whose performance depends heavily on one quarter.

Strategic capital also looks more important than it did at the beginning of the period. Pharma companies are increasingly showing up around platforms that already combine AI with experimental systems, proprietary pipelines and a credible route into clinical development.

The most misleading takeaway would be that AI drug discovery funding simply went from $185M to $2.3B and therefore became more than ten times stronger. What actually happened is more interesting: a functioning early-stage market continued underneath, the middle expanded sharply and then cooled, and a small number of platforms became capable of raising amounts that barely existed in this market a few quarters earlier.